Rhumbline Advisers Purchases 5,771 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Rhumbline Advisers has increased its stake in Kymera Therapeutics by 9.0%, now owning approximately 69,928 shares valued at $1.9 million.
• Kymera Therapeutics reported a loss of $0.95 per share for the latest quarter, missing estimates, with revenue declining by 55.1% year-over-year to $11.48 million.
• The stock currently has a consensus rating of "Buy" from analysts, with price targets ranging from $51.00 to $64.00.

Rhumbline Advisers lifted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 69,928 shares of the company's stock after purchasing an additional 5,771 shares during the period. Rhumbline Advisers owned 0.11% of Kymera Therapeutics worth $1,914,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Siren L.L.C. increased its stake in shares of Kymera Therapeutics by 9.1% during the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after purchasing an additional 270,580 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Kymera Therapeutics in the 4th quarter valued at approximately $344,000. GAMMA Investing LLC grew its stake in Kymera Therapeutics by 3,851.5% in the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after buying an additional 6,509 shares in the last quarter. Millennium Management LLC grew its stake in Kymera Therapeutics by 205.0% in the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after buying an additional 77,912 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kymera Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock valued at $1,163,000 after buying an additional 2,011 shares in the last quarter.

Analysts Set New Price Targets

KYMR has been the subject of several analyst reports. Royal Bank Of Canada initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, September 16th. They issued an "outperform" rating and a $70.00 price target for the company. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $70.00 target price for the company. Wells Fargo & Company cut their target price on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, June 26th. HC Wainwright upped their price target on shares of Kymera Therapeutics from $60.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target for the company in a research report on Monday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Buy" and an average target price of $59.95.

Kymera Therapeutics Trading Down 4.0%

Shares of KYMR stock traded down $2.03 during midday trading on Friday, reaching $49.13. 2,555,812 shares of the stock were exchanged, compared to its average volume of 789,971. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $53.27. The company's 50 day moving average is $43.85 and its two-hundred day moving average is $37.96. The firm has a market cap of $3.51 billion, a PE ratio of -14.16 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm had revenue of $11.48 million for the quarter, compared to analysts' expectations of $17.37 million. During the same quarter last year, the company posted ($0.58) EPS. The firm's revenue was down 55.1% on a year-over-year basis. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 79,220 shares of the firm's stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the transaction, the chief financial officer owned 227,409 shares of the company's stock, valued at approximately $11,370,450. This trade represents a 25.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker bought 655,500 shares of the firm's stock in a transaction on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the purchase, the director directly owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. This represents a 12.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.01% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.